On 2 June 2026, South Korean-headquartered Daewoong Pharmaceutical and Chinese-based global biologics contract development and manufacturing organisation (CDMO), Chime Biologics, announced that they have entered a strategic partnership agreement for the development, manufacture and commercialisation of a biosimilar of Sanofi/Regeneron’s Dupixent® (dupilumab).
Under the agreement, Chime will support the development and manufacture of Daewoong’s dupilumab biosimilar, while both companies will collaborate on commercialisation.
Although Daewoong has previously partnered on biosimilars in the Korean market (for example, promoting and launching Celltrion’s denosumab biosimilars in Korea), the dupilumab agreement with Chime is intended to be the foundation of its biologics expansion strategy, building the Dupixent® biosimilar into a global product.
Biosimilar dupilumab is under development by at least Samsung Bioepis, Bio-Thera Solutions and Costa Rican-based SteinCares, Alvotech and Advanz, Binnopharm and Mabwell and Amneal. In August 2025, CSPC Pharmaceutical announced that it received approval from China’s National Medical Products Administration (NMPA) to conduct clinical trials of its dupilumab injection. In January 2026, Chong Kun Dang received approval from the EMA and UK MHRA for its phase 1 clinical trial protocol for CKD-706 (dupilumab).